It sure seems strange that we had a very well orchestrated 100% move on fairly low volume (for a stock with 250M OS) to be followed by a no move on extremely low volume while we PR 2 good bits of data (seemingly written by an overly somber undertaker)but for some reason hold back on the trial results from the earliest and most advanced trials in Georgia. Trials results that could either begin to really explain the strength or weakness of Bavi.
I am sure there is a very good reason for all this.
I'm no expert in reading study results but does anyone else find it odd that both reports listed identical results - "6 partial tumor responses and 1 complete tumor response".
Would appreciate some clarification if I'm missing something.
News 
Market Data 
Discover 
AI
